X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs DR. DATSONS LABS - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH DR. DATSONS LABS PANACEA BIOTECH/
DR. DATSONS LABS
 
P/E (TTM) x 171.2 -10.9 - View Chart
P/BV x 3.8 0.2 2,342.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   DR. DATSONS LABS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
DR. DATSONS LABS
Mar-14
PANACEA BIOTECH/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs149126 118.4%   
Low Rs8231 266.3%   
Sales per share (Unadj.) Rs84.1133.0 63.3%  
Earnings per share (Unadj.) Rs-18.30.2 -12,075.0%  
Cash flow per share (Unadj.) Rs-6.76.6 -101.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.7128.8 65.0%  
Shares outstanding (eoy) m61.2531.66 193.5%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x1.40.6 233.3%   
Avg P/E ratio x-6.3516.1 -1.2%  
P/CF ratio (eoy) x-17.211.8 -145.6%  
Price / Book Value ratio x1.40.6 227.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0742,477 285.6%   
No. of employees `0002.8NA-   
Total wages/salary Rs m1,44956 2,587.9%   
Avg. sales/employee Rs Th1,874.1NM-  
Avg. wages/employee Rs Th527.0NM-  
Avg. net profit/employee Rs Th-407.7NM-  
INCOME DATA
Net Sales Rs m5,1544,211 122.4%  
Other income Rs m10079 126.8%   
Total revenues Rs m5,2544,289 122.5%   
Gross profit Rs m-766569 -134.8%  
Depreciation Rs m711204 347.8%   
Interest Rs m1,503430 349.4%   
Profit before tax Rs m-2,88113 -22,681.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-6-2 316.7%   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m176 275.4%   
Profit after tax Rs m-1,1215 -23,360.4%  
Gross profit margin %-14.913.5 -110.1%  
Effective tax rate %-0.648.0 -1.2%   
Net profit margin %-21.80.1 -19,085.1%  
BALANCE SHEET DATA
Current assets Rs m3,8106,852 55.6%   
Current liabilities Rs m8,3656,711 124.7%   
Net working cap to sales %-88.43.3 -2,639.3%  
Current ratio x0.51.0 44.6%  
Inventory Days Days156161 96.8%  
Debtors Days Days67318 21.1%  
Net fixed assets Rs m14,4803,673 394.2%   
Share capital Rs m61317 19.4%   
"Free" reserves Rs m9033,761 24.0%   
Net worth Rs m5,1274,078 125.7%   
Long term debt Rs m5,8321,671 349.0%   
Total assets Rs m19,43312,633 153.8%  
Interest coverage x-0.91.0 -89.0%   
Debt to equity ratio x1.10.4 277.6%  
Sales to assets ratio x0.30.3 79.6%   
Return on assets %2.03.4 57.0%  
Return on equity %-21.90.1 -18,577.8%  
Return on capital %3.67.7 47.4%  
Exports to sales %24.522.9 107.1%   
Imports to sales %10.214.3 71.2%   
Exports (fob) Rs m1,264964 131.1%   
Imports (cif) Rs m525602 87.2%   
Fx inflow Rs m1,539964 159.7%   
Fx outflow Rs m942607 155.2%   
Net fx Rs m597357 167.3%   
CASH FLOW
From Operations Rs m5991,345 44.6%  
From Investments Rs m-438-2,256 19.4%  
From Financial Activity Rs m-303-1,200 25.2%  
Net Cashflow Rs m-141-2,111 6.7%  

Share Holding

Indian Promoters % 74.5 4.5 1,644.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 0.0 -  
FIIs % 1.3 1.4 96.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 94.1 25.1%  
Shareholders   10,259 20,807 49.3%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DIVIS LABORATORIES  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Jan 23, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS